Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival

A comparative study with prostaglandin E1

Shigeru Ichioka, Takashi Nakatsuka, Yuko Sato, Masahiro Shibata, Akira Kamiya, Kiyonori Harii

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background. Amrinone, a selective phosphodiesterase (PDE) III inhibitor, is a newly developed agent that possesses a combination of positive inotropic and vasodilating properties as a result of preventing the degradation of cAMP and it has recently been licensed for treatment of heart failure alone. Amarinone is expected to be useful for the treatment not only of heart failure but also of peripheral circulatory disorders, including vascular disease, and for ischemic flaps, because it improves microcirculatory hemodynamics. To investigate potential therapeutic applications of amarinone, we evaluated its ability to improve microcirculatory hemodynamics and flap survival. Materials and methods. The rat skinfold chamber technique was employed to quantify microcirculation directly in vivo. The improved survival area of random flaps in rats treated with amrinone was examined to assess therapeutic efficacy of this drug. Its effects were compared with those of prostaglandin E1 (PGE1), which has been widely approved as an agent for improving hemodynamics. Results. Microcirculatory blood flow and flap survival area were significantly increased in both amrinone- and PGE1- treated animals, compared to the saline-treated controls. The ameliorating effects of amrinone were comparable to those of PGE1. Conclusions. The results of this study suggest amrinone to be a potentially useful drug not only for treating heart failure but also for improving microcirculation in patients with vascular diseases and for postoperative care after reconstructive surgery.

Original languageEnglish
Pages (from-to)42-48
Number of pages7
JournalJournal of Surgical Research
Volume75
Issue number1
DOIs
Publication statusPublished - 1998 Feb 15
Externally publishedYes

Keywords

  • Aminone
  • Blood flow
  • Flap survival
  • Hemodynamic
  • Microcirculation
  • Phosphodiesterase inhibitor

ASJC Scopus subject areas

  • Surgery

Cite this

Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival : A comparative study with prostaglandin E1. / Ichioka, Shigeru; Nakatsuka, Takashi; Sato, Yuko; Shibata, Masahiro; Kamiya, Akira; Harii, Kiyonori.

In: Journal of Surgical Research, Vol. 75, No. 1, 15.02.1998, p. 42-48.

Research output: Contribution to journalArticle

Ichioka, Shigeru ; Nakatsuka, Takashi ; Sato, Yuko ; Shibata, Masahiro ; Kamiya, Akira ; Harii, Kiyonori. / Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival : A comparative study with prostaglandin E1. In: Journal of Surgical Research. 1998 ; Vol. 75, No. 1. pp. 42-48.
@article{39c6868667db4b3899b68d35874e4146,
title = "Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival: A comparative study with prostaglandin E1",
abstract = "Background. Amrinone, a selective phosphodiesterase (PDE) III inhibitor, is a newly developed agent that possesses a combination of positive inotropic and vasodilating properties as a result of preventing the degradation of cAMP and it has recently been licensed for treatment of heart failure alone. Amarinone is expected to be useful for the treatment not only of heart failure but also of peripheral circulatory disorders, including vascular disease, and for ischemic flaps, because it improves microcirculatory hemodynamics. To investigate potential therapeutic applications of amarinone, we evaluated its ability to improve microcirculatory hemodynamics and flap survival. Materials and methods. The rat skinfold chamber technique was employed to quantify microcirculation directly in vivo. The improved survival area of random flaps in rats treated with amrinone was examined to assess therapeutic efficacy of this drug. Its effects were compared with those of prostaglandin E1 (PGE1), which has been widely approved as an agent for improving hemodynamics. Results. Microcirculatory blood flow and flap survival area were significantly increased in both amrinone- and PGE1- treated animals, compared to the saline-treated controls. The ameliorating effects of amrinone were comparable to those of PGE1. Conclusions. The results of this study suggest amrinone to be a potentially useful drug not only for treating heart failure but also for improving microcirculation in patients with vascular diseases and for postoperative care after reconstructive surgery.",
keywords = "Aminone, Blood flow, Flap survival, Hemodynamic, Microcirculation, Phosphodiesterase inhibitor",
author = "Shigeru Ichioka and Takashi Nakatsuka and Yuko Sato and Masahiro Shibata and Akira Kamiya and Kiyonori Harii",
year = "1998",
month = "2",
day = "15",
doi = "10.1006/jsre.1998.5266",
language = "English",
volume = "75",
pages = "42--48",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival

T2 - A comparative study with prostaglandin E1

AU - Ichioka, Shigeru

AU - Nakatsuka, Takashi

AU - Sato, Yuko

AU - Shibata, Masahiro

AU - Kamiya, Akira

AU - Harii, Kiyonori

PY - 1998/2/15

Y1 - 1998/2/15

N2 - Background. Amrinone, a selective phosphodiesterase (PDE) III inhibitor, is a newly developed agent that possesses a combination of positive inotropic and vasodilating properties as a result of preventing the degradation of cAMP and it has recently been licensed for treatment of heart failure alone. Amarinone is expected to be useful for the treatment not only of heart failure but also of peripheral circulatory disorders, including vascular disease, and for ischemic flaps, because it improves microcirculatory hemodynamics. To investigate potential therapeutic applications of amarinone, we evaluated its ability to improve microcirculatory hemodynamics and flap survival. Materials and methods. The rat skinfold chamber technique was employed to quantify microcirculation directly in vivo. The improved survival area of random flaps in rats treated with amrinone was examined to assess therapeutic efficacy of this drug. Its effects were compared with those of prostaglandin E1 (PGE1), which has been widely approved as an agent for improving hemodynamics. Results. Microcirculatory blood flow and flap survival area were significantly increased in both amrinone- and PGE1- treated animals, compared to the saline-treated controls. The ameliorating effects of amrinone were comparable to those of PGE1. Conclusions. The results of this study suggest amrinone to be a potentially useful drug not only for treating heart failure but also for improving microcirculation in patients with vascular diseases and for postoperative care after reconstructive surgery.

AB - Background. Amrinone, a selective phosphodiesterase (PDE) III inhibitor, is a newly developed agent that possesses a combination of positive inotropic and vasodilating properties as a result of preventing the degradation of cAMP and it has recently been licensed for treatment of heart failure alone. Amarinone is expected to be useful for the treatment not only of heart failure but also of peripheral circulatory disorders, including vascular disease, and for ischemic flaps, because it improves microcirculatory hemodynamics. To investigate potential therapeutic applications of amarinone, we evaluated its ability to improve microcirculatory hemodynamics and flap survival. Materials and methods. The rat skinfold chamber technique was employed to quantify microcirculation directly in vivo. The improved survival area of random flaps in rats treated with amrinone was examined to assess therapeutic efficacy of this drug. Its effects were compared with those of prostaglandin E1 (PGE1), which has been widely approved as an agent for improving hemodynamics. Results. Microcirculatory blood flow and flap survival area were significantly increased in both amrinone- and PGE1- treated animals, compared to the saline-treated controls. The ameliorating effects of amrinone were comparable to those of PGE1. Conclusions. The results of this study suggest amrinone to be a potentially useful drug not only for treating heart failure but also for improving microcirculation in patients with vascular diseases and for postoperative care after reconstructive surgery.

KW - Aminone

KW - Blood flow

KW - Flap survival

KW - Hemodynamic

KW - Microcirculation

KW - Phosphodiesterase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0032519325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032519325&partnerID=8YFLogxK

U2 - 10.1006/jsre.1998.5266

DO - 10.1006/jsre.1998.5266

M3 - Article

VL - 75

SP - 42

EP - 48

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -